Molecular Imaging Insight - March 2008 - (Page 9) ery period translates into fewer motion artifacts. In fact, ammonia MPI could be the new paradigm in cardiac stress testing. “Although 95 percent of patients still undergo conventional nuclear stress testing, a growing amount of clinical research shows cardiac PET imaging is superior,” shares Miller. Several clinical studies have reported that cardiac PET stress/ rest imaging results in a higher diagnostic accuracy than SPECT imaging. (See SPECT and PET in the Evaluation of Coronary Artery Disease, RadioGraphics 1999; 19:915-926; Impact of Myocardial Perfusion Imaging with PET and 82Rb on Downstream Invasive Procedure Utilization, Costs and Outcomes in Coronary Disease Management, J Nucl Med 2007; 48:1069-1076; and Clinical cardiac positron emission tomography: State of the Art, Circulation 1991;84(Suppl I):I-22—I-36. Perfusion imaging with ammonia requires precise timing and attention to detail to maximize patient throughput and minimize scan time. Currently, Premier PET Imaging offers six ammonia MPI slots weekly. On the ammonia MPI day, PETNET Solutions schedules one radiopharmacist for an afternoon shift and converts its cyclotron from FDG to ammonia production. Although patients are scheduled, the PET center does not place the order for ammonia until the patient arrives. As the PETNET Solutions radiopharmacist prepares the dose, the PET center readies the patient by completing paperwork, starting an IV and placing EKG leads. Typically, the ammonia dose arrives as the technologist starts the six-minute adenosine stress test. Midway through the stress portion of the study, the tech injects the ammonia, which gives the patient several minutes to recover from the stress portion of the study. As the patient’s heart rate and pulse return to normal, the PET acquisition begins. “We’ve had a very positive response from patients and referring physicians,” confirms Miller. In fact, the positive response is likely to grow the business. “The potential to increase the business is immense. We are under pressure to offer the procedure to more patients,” says Miller. Premier PET Imaging aims to meet local demands by tripling the number of slots dedicated to cardiac imaging. The limiting factor, says Miller, is the availability of ammonia. “Right now, cardiac imaging plays second fiddle to oncology imaging, but the market is rapidly changing.” The clinical rationale is sound, and demand for perfusion imaging is high. On the business side, more radiopharmacy sites are investing in two cyclotrons, providing the flexibility to dedicate more time to ammonia production. Ammonia PET MPI is clearly impacting patient management as well as proving to be quite cost-effective. A European study released last fall showed that PET changed patient management in 78% of the patients in a cost-effective fashion. (See: 13N-ammonia myocardial perfusion imaging with a PET/CT scanner: impact on clinical decision making and cost-effectiveness, Eur J Nucl Med Mol Imaging, 2007 Dec 5, DOI 10.1007/s00259-007-0647-3. Another study released last year in the Journal of Nuclear Medicine found that PET MPI performed in patients with intermediate preMolecularImaging.net test likelihood of coronary disease resulted in a 50% reduction in coronary angiograms, 30% cost savings and excellent clinical outcomes at one year when compared to SPECT imaging. (See: Impact of Myocardial Perfusion Imaging with PET and 82Rb on Downstream Invasive Procedure Utilization, Costs and Outcomes in Coronary Disease Management, J Nucl Med 2007; 48:1069-1076.) “This procedure is a finely orchestrated assembly line. Centers need to assess traffic congestion and transport time at several times of day prior to beginning a program to minimize the chance of dose expiring during transport.” Darren Miller, chief technical advisor, Premier PET Imaging of Jacksonville, Fla. Starting a program It takes a fair amount of planning to begin an ammonia MPI program1. Currently, the half-life of ammonia limits availability to sites within a 20-minute radius of PETNET Solutions. “This procedure is a finely orchestrated assembly line. Centers need to assess traffic congestion and transport time at several times of day prior to beginning a program to minimize the chance of a dose expiring during transport,” explains Miller. The other prerequisite is a solid relationship between the PET center and the radiopharmacy. The program is a partnership that requires trust. The center needs to count on timely dose transportation, and the radiopharmacy requires volume to justify the cost of ammonia generation. Other critical infrastructure includes staffing and education. Premier PET Imaging turns to an on-staff nuclear cardiologist to oversee the lion’s share of the ammonia MPI program and interprets the data. The supervising physician monitors the patients and administers the ammonia and adenosine. “It’s very important that a subspecialist is available and able to answer any questions a referring physician might have about the study,” Fagien says. The practice also implemented an educational marketing campaign to inform area cardiologists and non-cardiac referring physicians about the utility and benefits of perfusion imaging. An improved paradigm Ammonia MPI offers a best-of-both-worlds option. Image quality is superior to traditional nuclear cardiac stress testing and has long been considered the gold standard in MPI. Compared to traditional stress testing, ammonia MPI is more convenient for patients, and equally important, it allows PET centers to expand their clinical offerings and market a new service. “PET perfusion scans are another example of how the education and appropriate utilization of certain modalities parlays into both better clinical medicine and business,” sums Fagien. 1 Pending PETNET pilot program evaluation March 2008 | Molecular Imaging Insight http://jnm.snmjournals.org/cgi/content/abstract/48/7/1069 http://radiographics.rsnajnls.org/cgi/content/abstract/19/4/915 http://jnm.snmjournals.org/cgi/content/abstract/48/7/1069 http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=1884490&cmd=showdetailview&indexed=google http://www.springerlink.com/content/p80h32328l1v7045 http://www.springerlink.com/content/p80h32328l1v7045 http://www.springerlink.com/content/p80h32328l1v7045 http://MolecularImaging.net
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.